

## drug safety

## FORUM 20

A Patient First Approach to Translational Safety. From Nonclinical to Clinical Wellcome Collection, 183 Euston Road, London October 17th 2024

9am - 5pm

## The programme is beginning to take shape:

Time	Title	Speaker
9:00 - 9:45	Arrival and Registration - Coffee and Pastries	
9:45 - 10:00	Introduction	Dr Richard Knight, ApconiX
Opening Keynote		
10:00 - 10:30	Translational Safety [Medicines] by Examples	Dr Steffen Ernst, ApconiX
Morning Session		
10:30 - 11:00	Translational Safety - from Strategy to Implementation	Dr Peter Schulz, Explic8
11:00 - 11:30	Designing Preclinical Packages to Support Risk Assessment for Reproduction	Dr Jane Stewart, ApconiX
11:30 - 12:00	Nonclinical Prediction & Evaluation Strategies to Minimize Drug-induced Liver Injuries	Dr Dominic Williams, AstraZeneca
12:00 - 13:00	Lunch Break	
Afternoon Session		
13:00 - 13:30	Understanding Cereblon Neosustrate Safety: a Key Approach for De-risking Targeted Protein Degraders	Dr James Sidway, ApconiX
13:30 - 14:00	Making Decisions in the Face of Complex Data: a Carcinogenicity Assessment Case Study	Dr Adrian Fowkes, Lhasa Limited
14:00 - 14:30	Benefits of Early Screening for Detection of Seizure Liability: Utility of In Vitro Assays for Problem Solving and Decision Making	Dr Kimberly Rockley, ApconiX
14:30 - 15:00	Coffee/Tea	
15:00 - 15:30	Nonclinical Approaches Providing Improved Translational Safety for Inhaled Products	Professor Victoria Hutter, ImmuONE
15:30 - 16:00	TBC	David Jones, ApconiX
16:00 - 16:30	Ask the Experts Q&A Chair: Dr Steffen Ernst	Dr Jane Stewart Dr Peter Schulz TBC
16:30	Close	
		0.11 01